Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
74.89 USD | +1.53% | +5.23% | -5.91% |
04-30 | North American Morning Briefing : More Earnings -2- | DJ |
04-29 | Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.91% | 3.5B | |
-4.24% | 86.85B | |
+2.76% | 40.16B | |
-16.48% | 31.28B | |
+57.86% | 25.27B | |
-13.58% | 15.33B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
+6.89% | 8.83B | |
-10.53% | 7.94B |
- Stock Market
- Equities
- AXSM Stock
- News Axsome Therapeutics, Inc.
- Axsome Therapeutics : Cantor Fitzgerald Adjusts Axsome Therapeutics' Price Target to $161 from $131, Keeps Overweight Rating